Current interest in the effects of incretin-based therapy, including GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, is intense due to effects on weight loss, as well as diabetes treatment. This evidence concerns the gene GLP1R and diabetes mellitus.